https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-continued-clinical-progress-and-updates-to-management
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-participate-in-upcoming-investor-conferences-2021-11-11
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-four-posters-highlighting-preclinical-data-from-its
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-third-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-first-patient-dosed-in-phase-i-ii-trial-of-bicycler-1
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-publication-of-article-highlighting-preclinical-data-0
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-expansion-of-genentech-immuno-oncology-collaboration
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-closing-of-public-offering-of-american-depositary
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-pricing-of-upsized-public-offering-of-%24175-million-of
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-proposed-%24125000000-public-offering-of-american
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-interim-bt5528-phase-i-clinical-trial-results-and
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-bt5528-interim-phase-i-data-at-aacr-nci-eortc-virtual
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-participate-in-upcoming-investor-conferences-2021-09-01
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-second-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/ionis-reports-second-quarter-2021-financial-results-and-recent-business-achievements
https://www.nasdaq.com/press-release/ionis-enters-exclusive-licensing-agreement-with-bicycle-therapeutics-aimed-at-further
https://www.nasdaq.com/press-release/bicycle-therapeutics-enters-exclusive-license-and-collaboration-agreement-with-ionis
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-restrictions-on-shareholder-attendance-at-annual
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-2021-05
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-presentations-at-the-aacr-annual-meeting-2021-2021-04
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-significant-progress-across-multiple-therapeutic
https://www.nasdaq.com/press-release/bicycle-therapeutics-appoints-jose-carlos-gutierrez-ramos-ph.d.-to-its-board-of
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-at-the-oppenheimer-31st-annual-healthcare-conference
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-publication-of-article-highlighting-preclinical-data
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-pipeline-progress-update-2021-01-14
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-at-the-2020-piper-sandler-healthcare-conference-2020
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b.v.
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-at-the-jefferies-virtual-london-healthcare-conference
https://www.nasdaq.com/press-release/bicycle-therapeutics-presents-posters-at-the-sitc-35th-anniversary-annual-meeting
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-expansion-of-scientific-advisory-board-2020-10-21
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-posters-at-the-sitc-35th-anniversary-annual-meeting
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-gross-proceeds-of-%2450.0-million-from-its-at-the-market
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-trials-in-progress-poster-for-bt8009-at-the-esmo
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-first-patient-dosed-in-phase-i-ii-trial-of-bicycler-0
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-2020-09
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-first-patient-dosed-in-phase-iia-trial-of-bicycler
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-first-patient-dosed-in-oxurions-phase-ii-trial-using-a
https://www.nasdaq.com/press-release/bicycle-therapeutics-appoints-dr.-dominic-smethurst-as-chief-medical-officer-2020-08
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-at-the-canaccord-genuity-40th-annual-growth
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/bicycle-therapeutics-appoints-sir-keith-peters-as-chairman-of-its-scientific-advisory
https://www.nasdaq.com/press-release/bicycle-therapeutics-presents-new-translational-data-for-bt5528-and-preclinical-data
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-at-upcoming-investor-conferences-2020-05-27
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-new-translational-research-for-bt5528-and-preclinical
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-trials-in-progress-poster-for-bt5528-at-the-2020
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-publication-of-bt5528-mechanism-of-action-in-aacr
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-present-at-the-bank-of-america-2020-health-care-conference
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-first-patient-dosed-in-phase-i-dose-escalation-of
https://www.nasdaq.com/press-release/bicycle-therapeutics-appoints-zafar-qadir-as-general-counsel-2020-04-23
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-pipeline-progress-update-2020-04-07
https://www.nasdaq.com/press-release/bicycle-therapeutics-to-participate-in-a-panel-discussion-at-the-canaccord-genuity
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-exclusive-strategic-collaboration-with-genentech-to
https://www.nasdaq.com/press-release/bicycle-therapeutics-and-cancer-research-uk-to-collaborate-on-development-of-new
https://www.nasdaq.com/press-release/bicycle-therapeutics-announces-first-patient-dosed-in-phase-i-ii-trial-of-bicycler
https://www.nasdaq.com/press-release/bicycle-therapeutics-reports-third-quarter-2019-financial-results-and-corporate
